Neuroblastic tumors (NTs) include the neuroblastomas, ganglioneuroblastomas and ganglioneuromas. We have reported previously that the calcium-sensing receptor is expressed in differentiated, favorable NTs but almost undetectable in unfavorable neuroblastomas. We have now detected hypermethylation of a particular region within the CpG island encompassing the CaSR gene promoter 2 in neuroblastoma cell lines and 25% primary neuroblastomas. Hypermethylation of this region was associated with reduced CaSR messenger RNA expression and several predictors of poor outcome in neuroblastomas, including MYCN amplification. Treatment with 5′aza-2-deoxycitidine and/or trichostatin A restored CaSR expression in MYCN-amplified cell lines. Following 5′aza-2-deoxycitidine exposure, decreased percentages of methylated CpG sites were observed at the above-mentioned region. By interphase fluorescence in situ hybridization, variable percentages of nuclei with monosomy of chromosome 3, where the human CaSR gene resides, were observed in more than 90% of primary NTs of all subgroups. Nuclei harboring this alteration were heterogeneously distributed among tumor cells. Ectopic overexpression of the calcium-sensing receptor in two MYCN-amplified neuroblastoma cell lines in which this gene is silenced by promoter hypermethylation significantly reduced their in vitro proliferation rates and almost abolished their capacity to generate xenografts in immunocompromised mice. Finally, upon acute exposure to calcium, the primary activator of this receptor, calcium-sensing receptor-overexpressing neuroblastoma cells underwent apoptosis, a process dependent on sustained activation of ERK1/2. These data would support the hypothesis that epigenetic silencing of the CaSR gene is neither an in vitro artefact in neuroblastoma cell lines nor an irrelevant, secondary event in primary NTs, but a significant mechanism for neuroblastoma survival.
Introduction
Neuroblastic tumors arise from precursor cells of the peripheral nervous system and include the neuroblastomas, ganglioneuroblastomas and ganglioneuromas. This is a highly heterogeneous group of developmental malignancies that may undergo spontaneous regression, expand as a confined mass or proliferate aggressively both locally and at distant sites (1, 2) . Several biological abnormalities have been associated with this variety of clinical presentations, including alterations of ploidy, deletions or gains of recurrent chromosomal regions and the amplification of the MYCN oncogene (3) (4) (5) (6) (7) .
Neuroblastic tumors are composed of different proportions of neuroblasts and non-neuronal, glial-like cells. Neuroblastoma cell lines reflect this cellular heterogeneity and three phenotypic variants have been characterized: Neuroblastic (N-type) cells, substrate-adherent (S-type) glial-like cells and cells with intermediate phenotype (I-type). The latter show features of both N-type and S-type cells, are able to differentiate along both lineages and have the highest tumorforming capacities among the three subtypes (8, 9) .
Histologically, neuroblastic tumors with an advanced degree of differentiation are associated with good outcome (10) . Some molecular pathways involved in neuroblastoma maturation processes have been uncovered (11) (12) (13) . We have described that the calcium-sensing receptor (CaSR) is expressed in differentiated, favorable neuroblastic tumors, and it is upregulated upon differentiation induction (14) .
The CaSR is a family C G-protein coupled receptor (GPCR) whose primary role is to regulate the secretion of parathyroid hormone to maintain calcium plasmatic concentrations within a very narrow range (15) . The CaSR is also expressed in many tissues not involved in calcium metabolism and in a number of malignancies (16) , but divergent and even opposite functions have been attributed to this receptor in different neoplasias. For instance, in prostate cancer models, CaSR activation has been associated with tumor cell proliferation and bone metastases (17) . Conversely, in the parathyroid glands (18) and the colonic epithelium (19) , the CaSR expression is high in differentiated normal cells, reduced in adenomas and almost abolished in highly proliferating, undifferentiated carcinomas. The reasons why this GPCR would act as an oncogene in some neoplasias but displays a pattern of expression reminiscent of a tumor-suppressor gene in others are presently unknown.
The human CaSR gene resides on the chromosomal region 3q13.3-21. It contains six coding exons and two alternatively transcribed first non-coding exons, 1A and 1B. They are, respectively, under the control of promoter 1 and promoter 2 (P2) and the latter has been described to lie in a GC-rich region (20) . However, the mechanisms of transcriptional regulation responsible for decreased expression of the CaSR in some neoplasias compared with their normal counterparts are only partially understood.
We have analyzed genetic and epigenetic mechanisms potentially responsible for downregulation of the CaSR gene in neuroblastic tumors. Also, the in vitro and in vivo effects of its overexpression and activation have been examined.
Collection of Cell Cultures. Cells were grown in Roswell Park Memorial Institute (RPMI)-1640 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 2 mM l-glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml), at 37°C and 5% CO 2 . Mycoplasma PCR tests were routinely performed (Reactiva, Spain). Characterization of cell lines included analysis of MYCN status by quatitative PCR (qPCR) as described (21) and expression analysis of several transcripts to assess their phenotype according to reported data previously (see below).
In vitro treatment with 5-aza-2′-deoxycytidine and/or trichostatin A
Neuroblastoma cell lines were exposed to 1 µM 5-aza-2′-deoxycytidine (Aza) for 72 h and/or with 100 nM trichostatin A (TSA) for 12 h (Sigma, St. Louis, MO). Vehicle-treated cells were processed simultaneously. Experiments were repeated at least twice independently.
RNA isolation, complementary DNA synthesis, PCR and qPCR
Total RNA was isolated using TriReagent (Sigma). Retrotranscription and PCR were performed as described (14) . Quantitative PCR analyses were performed in a 7000 SDS system using gene-specific Assays on Demand and Taqman Universal PCR Master Mix (Applied Biosystems, Forster City, CA). Relative expression levels were calculated according to the 2 -ΔΔCt method using TATA-box binding protein (TBP) as housekeeping gene. Only samples with a TBP Ct lower than 30 were used to ensure RNA and complementary DNA quality. CaSR mRNA levels in tumors were normalized to those of sample NT-35 and levels in transfected clones were normalized to clone SK-N-LP pCMV-CaSR-GFP-6. Transcript levels in cell lines were calculated relative to those of LA-N-1. Table 1 , available at Carcinogenesis Online. BSP-2 was carried out to amplify a specific region of P2 (−129 to −434). When hypermethylation (>6% methylated CpG sites in ≥10 clones) of this fragment was detected, the entire CpG island was sequenced. PCRs were performed with Taq Gold polymerase (Applied Biosystems). PCR products were cloned using TA cloning kit (Invitrogen) and minipreps were generated to sequence 10-16 clones.
Bisulfite-specific PCR

Methylation-specific PCR
Primers for detecting unmethylated and methylated alleles at P2 were designed at www.mspprimer.org (22) . Genomic DNA from peripheral blood, brain and kidney were used as controls for unmethylated P2. Peripheral blood DNA from a healthy donor was treated with SssI methylase (New England Biolabs, Beverly, MA) to generate positive controls for methylated alleles. A denaturation step (94°C-9 min) was followed by 34 cycles (94°C-20 s; annealing-20 s; 72°C-20 s) with different annealing temperatures for unmethylated and methylated alleles (primers and conditions in Supplementary Table 1, available at Carcinogenesis Online). PCR products were resolved in 3% agarose gels, stained with ethidium bromide and visualized with a Kodak Logic-1500 system.
Interphase fluorescence in situ hybridization.
Interphase FISH analyses were performed by a dual-color procedure on methanol-acetone fixed cells and 2 µm sections of formalin-fixed, paraffinembedded tumors as described (23) . Co-hybridizations were performed with a chromosome 3 centromeric probe (Kreatech, Amsterdam, The Netherlands) and a probe generated with BAC RP11-79M2 to hybridize with the human CaSR gene locus. After midiprep purification, this probe was labeled by nick translation using Spectum red deoxyuridine triphosphate (Vysis, Abbot Molecular, Germany). One hundred nuclei were evaluated in each tumor. Deletion was considered when only one copy of 3q13.3-21 was detected with at least two centromere copies (2:1, 3:1, etc); monosomy 3 when only one copy of 3q13.3-21 and one centromere copy were seen (1:1) and imbalance when at least two copies of 3q13.3-21 were observed with additional centromere copies (3:2, 4:2, etc). Cut-off value (15%) was defined in control tissues as mean percentage of nuclei with an alteration +3 standard deviations.
Stable transfections and in vitro proliferation assays
Two neuroblastoma cell lines (SK-N-LP and SK-N-JD) were transfected with pCMV-GFP or pCMV-CaSR-GFP (Origene, Rockville, MD) using Fugene-6 (Roche, Indianapolis, IN). After 15 days of G418 selection (800 µg/ml), single cell clones were generated by limiting dilutions and maintained in G418 (200 µg/ml). CaSR expression was monitored using reverse transcription (RT)-qPCR, western blot and direct fluorescence imaging. Immunoblots were carried out as described below, except for the CaSR-specific antibody (Acris, Aachen, Germany). Clones were further purified by cell sorting prior to proliferation assays. These were performed as described (24) .
Mouse xenograft model
Four to six-week-old female athymic Nude-Foxn1 nu/nu mice (Charles Rivers) were used. Experiments were performed as described (25) , except for the number of injected cells and a longer period of follow-up. Procedures were approved by the Institutional Animal Research Ethics Committee. Both flanks of each animal were injected subcutaneously with 10 7 cells in Matrigel:phosphate-buffered saline (Becton Dickinson, Franklin Lakes, NJ). Wild-type neuroblastoma cell lines (SK-N-LP and SK-N-JD) and pCMV-GFP clones (2 clones/cell line) were injected in right flanks and pCMV-CASR-GFP clones (3 clones/cell line) in left flanks. Tumors were measured thrice a week. Forty days after injections, animals were killed and tumors were weighed. Half specimen was formalin-fixed, paraffin-embedded and the other part was flash frozen in liquid nitrogen.
Immunohistochemistry
Immunohistochemical analysis of the CaSR was carried out as described (14) . A similar protocol was followed to assess Ki67, synaptophysin, caspase-3 activation and poly (ADP-ribose) polymerase (PARP) cleavage using specific primary antibodies (Cell Signaling Technology, Danvers, MA).
In vitro activation of the CaSR: cell viability, apoptosis and ERK1/2 analyses Wild-type SK-N-LP or SK-N-JD neuroblastoma cells, pCMV-GFP and pCMVCaSR-GFP transfected clones were plated in RPMI-1640 10% FBS. Next day, cells were switched to calcium-free Dulbecco's modified Eagle's medium supplemented with bovine serum albumin (0.2% w/v), 4 mM l-glutamine and 0.5 mM CaCl 2 for 16 h, followed by the same medium containing either 0.5 or 3 mM CaCl 2 for 48 h. Two pools of clones (pCMV-GFP and pCMV-CaSR-GFP) were prepared after checking a homogeneous behavior among clones with or without CaSR expression. Cell viability was measured with CellTiter96 Aqueous Cell proliferation Assay (Promega, Madison, WI). Absorbance was measured at 490 nm in an E-max microplate reader (Molecular Devices, Sunnyvale, CA). For each clone/cell line, proliferation rates were calculated as a fold increase of the absorbance measured at each time point relative to its corresponding absorbance at day 0 (determined 18 h after plating).
To quantify apoptotic nuclei, cells were fixed with 2% paraformaldehyde and stained with 2 µg/ml Hoechst 33342 (Invitrogen) for 10 min. Nuclei were visualized using a Nikon Eclipse TE2000-E microscope and a Hamamatsu ORCA-ER camera. Uniformly stained nuclei were scored as viable cells, whereas condensed or fragmented nuclei were scored as apoptotic using ImageJ-1.42q software.
Phosphorylation status of extracellular signal-regulated kinase (ERK1/2), caspase-3 activation and PARP cleavage were analyzed by immunoblot. Following serum deprivation, cells were exposed to 0.5 mM or 3 mM CaCl 2 . At indicated times, they were collected in ice-cold phosphate-buffered saline and lysed in 10 mM Tris-HCl pH = 6.8, 1 mM ethylenediaminetetraacetic acid , 150 mM NaCl, 1% sodium dodecyl sulfate. About 30 µg protein were electrophoresed in 8-14% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. Incubation with primary antibodies (ERK1/2, phospho-ERK1/2 Thr202/Tyr204, caspase-3 Asp175 and PARP Asp214 from Cell Signaling; GAPDH and βtubulin from Millipore, Temecula, CA) was followed by horseradish peroxidase-conjugated secondary antibodies (Promega). Immunoreactive bands were detected with enhanced chemiluminiscence reagents (Amersham Pharmacia, Piscataway, NJ). Selected experiments were performed with MEK inhibitor U0126 (Selleck Chemicals, Munich, Germany) applied 2 h before serum deprivation and along calcium exposure.
Statistical analysis
The χ 2 test was used to assess the correlation of P2 hypermethylation or CaSR expression below the median with the clinical and biological subgroups.
Comparison of means was performed by Mann-Whitney U or Student t-tests.
Elapsed time from time of diagnosis to an event or the end of follow-up was used to compute event-free survival and overall survival (OS) probabilities, according to the method of Kaplan and Meier (26) . The log-rank statistic was used to compare the event-free survival and OS probabilities between groups (27) . The prognostic significance of variables was assessed by Cox proportional models (28) . P < 0.05 was considered significant.
Results
Downregulation of the CaSR gene is associated with predictors of poor outcome in neuroblastoma
Levels of CaSR mRNA were analyzed in 40 primary tumors and in non-neoplastic tissues by RT-qPCR. In univariate analyses, CaSR mRNA levels below the median value were significantly associated with the histologic subgroup of undifferentiated neuroblastomas and with prognostic factors of poor outcome in neuroblastoma, including Tumor suppressor role of the CaSR in neuroblastoma MYCN amplification, clinical stage 4, age at diagnosis >18 months and unfavorable pathology (Table I and Supplementary Table 2 , available at Carcinogenesis Online). Low expression of the CaSR was also associated with worse OS rates (P = 0.026), although this was not an independent prognostic factor in multivariate analyses (data not shown).
Since the exact normal counterpart of neuroblastic tumors is unknown, expression of the CaSR was examined in normal adrenal glands, where many of these tumors are located. Levels of CaSR mRNA in the available specimens were higher than the median value of the cohort (Supplementary Table 2 , available at Carcinogenesis Online).
Among samples obtained at second-look surgery and relapse, levels of CaSR mRNA did not change in six of them compared with their matching primary tumors. However, a 2-to 30-fold increase of expression was seen in four specimens compared with corresponding primary tumors. Upregulation of the CaSR mRNA following treatment was only observed in specimens with morphological signs of cytodifferentiation (Supplementary Table 2 , available at Carcinogenesis Online).
The CaSR gene promoter 2 is hypermethylated in MYCN-amplified neuroblastoma cell lines and unfavorable neuroblastic tumors
Eight neuroblastoma cell lines were used for these experiments, after analyzing their MYCN amplification status (Supplementary Table 3 , available at Carcinogenesis Online) and expression of several transcripts, including the neuroblastoma-specific marker PHOX2B (Supplementary Figure 2 , available at Carcinogenesis Online). Results were concordant with data reported previously.
Initially, CaSR mRNA was only detectable in LA-N-1 ( Figure 1A ). To select the optimum concentration of (Aza), LA1-55n cells were exposed to 1, 2. A search for CpG islands was conducted in the sequence Homo sapiens calcium-sensing receptor gene, alternative promoters and exons 1A and 1B (GenBank AY116081). Criteria included: Island size > 200 bp, GC content > 50% and observed versus expected CpG content > 0.6. A CpG island 1189 bp long was found encompassing the last 139 bp of exon 1A (+436 to +641), the entire promoter 2, exon 1B and 170 bp in the flanking 3′ untranslated regions.
In two non-neoplastic tissues in which the CaSR is expressed (kidney and brain), <6% methylated CpG sites (mC) were found across the CpG island, whereas variable percentages of mC were detected in LA-N-1, LA1-55n, SK-N-BE(2)-C, SK-N-JD, SK-N-LP and LA1-5s cell lines. In SH-SY5Y and SK-N-AS cells, only 10-19% mC were found in exon 1A, whereas P2 and the rest of the CpG island were unmethylated ( Figure 2B, Supplementary Table 3 , available at Carcinogenesis Online).
In primary tumors, P2 hypermethylation was detected in 10/40 (25%) cases (Supplementary Table 2 , available at Carcinogenesis Online). In these specimens, the immediately preceding portion of exon 1A was also hypermethylated and some tumors had even higher percentages of mC in this location than in P2 (P2 will now indicate both regions). Conversely, <6% mC were found in the other regions of the CpG island. Hypermethylation of P2 was significantly associated with CaSR mRNA levels below the median value (P = 0.003), MYCN amplification, clinical stage 4, age at diagnosis >18 months, unfavorable pathology and the histologic subgroup of undifferentiated neuroblastoma (NB) ( Table I) . Patients with hypermethylated P2 had a significantly worse OS than patients with unmethylated P2 (P = 0.017), but this was not an independent predictor of outcome in multivariate analyses.
Samples obtained at second-look surgery (n = 9) and relapse (n = 3) were also analyzed (Supplementary Table 2 , available at Carcinogenesis Online). Hypermethylation of P2 had been previously found in five of their matching primary tumors. One of these cases had a similar level of CaSR expression before and after treatment, and the percentage of mC was slightly higher in the postchemotherapy sample (NT, 47) than in the primary tumor (NT, 2). In the other four patients, a 2-to 30-fold increase of the CaSR mRNA levels was observed after treatment. A modest reduction of mC was detected in two of these samples (NT, 46; NT, 51), whereas the percentage of mC was <6% in the other two (NT, 48; NT, 49).
A remarkable reduction of mC in P2 was also observed in LA1-55n cells exposed to Aza alone or in combination with TSA, whereas TSA alone did not modify the methylation status of this region ( Figure 2C , Supplementary Table 3, available at Carcinogenesis Online).
To further assess the methylation status of P2, methylation-specific PCR was performed. In neuroblastoma cell lines and tumors with hypermethylated P2, bands for unmethylated and methylated alleles were detected ( Figure 2D ), except for those cases in which the majority of mC were located in exon 1A (Supplementary Tables 2 and 3 , available at Carcinogenesis Online). *Univariate analyses using the χ2 test were performed to assess the correlation of P2 hypermethylation or CaSR expression below the median with the clinical and biological subgroups of neuroblastic tumors. P < 0.05 was considered significant.
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Monosomy of chromosome 3 is present in benign and malignant neuroblastic tumors
Interphase FISH was performed in 48 neuroblastic tumors (40 at diagnosis, 5 at second-look surgery and 2 at relapse) and 8 neuroblastoma cell lines. Among evaluable primary tumors, 31/34 (91%) harbored a percentage of nuclei with monosomy of chromosome 3 above the cut-off value (Supplementary Table 2 , available at Carcinogenesis Online). They were heterogeneously distributed among tumor cells and no association was found between levels of CaSR mRNA and the number of nuclei bearing this alteration in each sample. Monosomy 3 in ≥40% nuclei was associated with the more differentiated histologic subgroups, differentiating neuroblastomas, ganglioneuroblastomas and ganglioneuromas (P = 0.007). No evidence of this alteration was found in a differentiating neuroblastoma (NT, 29) but losses at the CaSR locus (40% imbalance, 10% deletion) were detected in 50% of its nuclei. Conversely, the only undifferentiated neuroblastoma in which 40% nuclei showed monosomy 3 was the tumor of a 10-year-old boy (NT, 1), which exhibited an indolent growth, as it is usually the case for neuroblastomas affecting older children.
In neuroblastoma cell lines, >75% nuclei were disomic, trisomic or tetrasomic (Supplementary Table 3 , available at Carcinogenesis Online). Monosomy 3, imbalances and deletions at the CaSR locus were infrequently detected.
Overexpression of the CaSR reduces neuroblastoma proliferation and tumorigenicity
Two MYCN-amplified neuroblastoma cell lines, SK-N-LP and SK-N-JD, in which the CaSR gene was silenced by promoter hypermethylation, were selected to examine the effects induced by stable transfection of this GPCR. They exhibited high expression of the 
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neuroblastoma-specific marker PHOX2B, and levels of neuronal and glial-like differentiation markers consistent with the I-type phenotype (Supplementary Table 3 (Supplementary Figure 4 , available at Carcinogenesis Online). However, pCMV-CaSR-GFP clones exhibited significantly reduced proliferation rates compared with wild-type cell lines and pCMV-GFP clones ( Figure 3A) . Moreover, only 4/45 (8.8%) xenografts were generated in nu/nu mice from CaSR-overexpressing clones compared with 30/30 (100%) controls and they were significantly smaller ( Figure 3B) . One of the four Following bisulfite modification of genomic DNA samples, methylation status of P2 was also analyzed by methylation-specific PSR in non-neoplastic tissues in which the CaSR is expressed (kidney, brain), neuroblastic primary tumors and neuroblastoma cell lines, as described in the section Materials and methods. Peripheral blood DNA from a healthy donor before and after treatment with Sss I methylase was used as control for unmethylated (U) and methylated (M) alleles. NTC: No-template control.
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tumors generated by CaSR-overexpressing clones was calcified. The other three specimens showed similar proliferation index (Ki67), percentage of necrotic areas and apoptotic cells than control xenografts (Supplementary Figure 4 , available at Carcinogenesis Online). In 2/3 of them, morphological signs of cytodifferentiation were observed together with increased expression of CaSR, parathyroid hormone-related protein (PTHrP), RAC1 and peripheral myelin protein 22 (PMP22) mRNA (Supplementary Figure 5 , available at Carcinogenesis Online). However, the most consistent finding was the remarkably reduced capacity of CaSR-overexpressing clones to produce xenografts in nu/nu mice, although they were generated from highly tumorigenic I-type neuroblastoma cell lines.
In vitro activation of the CaSR induces apoptosis of neuroblastoma cells dependent on sustained activation of ERK1/2
To gain further insight into the signaling pathways activated by the CaSR in neuroblastoma cells, wild-type SK-N-LP or SK-N-JD cells, pCMV-GFP and pCMV-CaSR-GFP clones were acutely exposed to 0.5 or 3 mM CaCl 2 . As expected, morphological signs of differentiation (neuron-like appearance and neurite extension) followed serum deprivation in both control and CaSR-overexpressing neuroblastoma cells. However, when the latter were exposed to 3 mM CaCl 2 , groups of cells progressively detached from each other, cell vacuolization gradually appeared and increasing numbers of dead cells were observed ( Figure 4A ). This phenomenon started approximately 6 h following calcium challenge and cell death was predominant 48 h later. Scattered dead cells were also seen in control cultures exposed to 3 mM CaCl 2 , although they continued to grow over the period examined.
Decreased viability of CaSR-overexpressing neuroblastoma cells was significant at 24 and 48 h after calcium exposure, and this happened at physiological (1.4 mM) and supraphysiological (3 mM) concentrations of calcium ( Figure 4B ), concurrent with increased In vitro proliferation assays were performed using the crystal violet method. For each clone/cell line, proliferation rates were calculated as a fold increase of the absorbance measured at each time point relative to its corresponding absorbance at day 0 (determined 18 h after plating). Proliferation rates of pCMV-CaSR-GFP clones were significantly reduced when compared with that of wild-type cell lines and pCMV-GFP clones (*P = 0.001). (B) Aliquots of 10 7 cells from wild-type SK-N-LP and SK-N-JD cell lines, pCMV-GFP and pCMV-CaSR-GFP transfected clones were injected subcutaneously in nu/nu mice. Xenografts were measured thrice a week and weighted after 40 days. Only four specimens developed from CaSR-overexpressing clones and their weight was significantly smaller than that of controls (*P < 0.001, **P < 0.0001). Tumor volume of xenografts obtained from CaSR-overexpressing clones was significantly smaller than volume of controls from day 27 onwards (*P < 0.001).
Fig. 4. CaSR activation induces apoptosis of neuroblastoma cell lines. Two MYCN-amplified neuroblastoma cell lines (SK-N-JD and SK-N-LP) in
which the CaSR gene is silenced by promoter hypermethylation were stably transfected with pCMV-GFP or pCMV-CaSR-GFP. Pools of pCMV-GFP and pCMV-CaSR-GFP clones were prepared. (A) Cells were plated in RPMI-1640 10% FBS. Next day, cells were switched to calcium-free Dulbecco's modified Eagle's medium supplemented with bovine serum albumin (0.2% w/v), 4 mM l-glutamine and 0.5 mM CaCl 2 for 16 h, followed by exposure to the same medium containing either 0.5 or 3 mM CaCl 2 for 48 h. Cell-cell detachment, massive vacuolization and non-refringent, floating dead cells were observed in CaSR-overexpressing neuroblastoma cells exposed to 3 mM CaCl 2 while control cultures continued to grow. This phenomenon was replicated at least three times. (B) Control and CaSR-overexpressing neuroblastoma cells were serum starved for 16 h and then exposed to different concentrations of CaCl 2 for 48 h. Cell viability was quantified with CellTiter96 Aqueous Cell proliferation Assay. Absorbance was measured at 490 nm. Graphic shows a significant decrease in the percentage of cell viability (*P < 0.001, **P < 0.0001) in CaSR-overexpressing cells compared with control neuroblastoma cells (mean and standard error of mean of two independent experiments). (C) Following the same experiment described in (A), cells were fixed and nuclei were stained with Hoechst 33342. Uniformly stained nuclei were scored as viable cells, whereas condensed or fragmented nuclei were scored as apoptotic using ImageJ-1.42q software. Graphic shows the significant increase (**P < 0.0001) in the percentage of Hoechst 33342-positive apoptotic nuclei in CaSR-overexpressing neuroblastoma cells compared with control cells (mean and standard error of mean of two independent experiments). (D) Total cells lysates were prepared at indicated times following the experiment described in (A). PARP cleavage and caspase-3 activation were analyzed by western blotting using glyceraldehyde 3-phosphate dehydrogenase as internal loading control. Results shown are representative of at least two independent immunoblots.
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numbers of Hoechst-positive apoptotic nuclei ( Figure 4C ). Moreover, exposure to 3 mM CaCl 2 in CaSR-overexpressing neuroblastoma cells resulted in caspase-3 activation and PARP cleavage. Both indicators of apoptosis were also activated in control cells, although at much lower levels ( Figure 4D) .
Finally, sustained phosphorylation of ERK1/2 was detected in CaSR-overexpressing neuroblastoma cells exposed to 3 mM CaCl 2 over the hours examined, whereas this activation was transient and weak in control cells ( Figure 5A ).
Upon treatment with MEK inhibitor U0126, ERK1/2 phosphorylation was notably reduced ( Figure 5B ). Concurrently, cell viability ( Figure 5C ) and activation of caspase-3 and PARP ( Figure 5D ) were detected at similar levels in control and CaSR-overexpressing neuroblastoma cells exposed to 3 mM CaCl 2 . All these features were replicated in the SK-N-JD neuroblastoma cell line (Supplementary Figure 6 , available at Carcinogenesis Online).
Discussion
The aim of this work was to evaluate genetic and epigenetic mechanisms potentially responsible for the transcriptional silencing of the CaSR gene in neuroblatic tumors and the effects promoted by its reexpression and activation.
To investigate whether this gene was inactivated by epigenetic mechanisms, neuroblastoma cell lines were exposed to Aza and TSA. Increased expression of the CaSR was seen in MYCN-amplified cell lines following this treatment, an indication that, at least in vitro, this gene was epigenetically silenced. A particular region was identified in the CpG island encompassing the CaSR gene promoter 2 in which decreased numbers of CpG sites were detected upon re-expression of the CaSR with Aza. This would indicate that hypermethylation of this portion of the CpG island is one of the epigenetic mechanisms that inactivate the CaSR gene in neuroblastoma.
Hypermethylation of this region was also seen in 25% primary neuroblastomas, in association with low levels of CaSR expression and several prognostic factors of poor outcome in these tumors, including MYCN amplification. A number of epigenetically silenced genes have been reported in neuroblastoma in association with MYCN amplification and poor outcome (29) (30) (31) (32) . Epigenetic inactivation of the CaSR gene has been also detected in advanced, undifferentiated colorectal carcinomas (33) .
To investigate genetic mechanisms that might contribute to downregulation of this GPCR in neuroblastic tumors, allelic losses at the CaSR locus were assessed by Interphase FISH. Monosomy of chromosome 3 was detected in the majority of primary tumors, and higher percentages of nuclei with this alteration were seen among differentiated histological subgroups. Heterozygous gene deletion promoted by monosomy has been described to be associated with significant loss of mRNA expression of specific genes (34) and monosomy 3 has previously been found in benign neuroblastic tumors by array-comparative genomic hybridization (aCGH) (35) . The higher sensitivity of the Interphase FISH allowed for the identification of variable percentages of nuclei harboring this alteration in the majority of tumors. However, in the specimens examined, monosomy 3 was not correlated with reduced levels of CaSR mRNA expression. This might be due, at least partially, to low percentages of nuclei bearing this alteration in most specimens and their heterogeneous distribution among tumor cells. Monosomy 3 has also been reported in two other neural-crest-derived neoplasms, pheochromocytomas (36) and uveal melanomas (37) , where it also shows a heterogeneous distribution. The functional consequences of monosomy 3 in these neoplasias remain to be established. However, we hypothesize that, in the context of malignant neuroblastomas, it might cooperate with epigenetic mechanisms of transcriptional silencing to inactivate the CaSR gene. Absence of monosomy 3 in neuroblastoma cell lines could be interpreted as a transitional clonal chromosomal abnormality (38) . Given that downregulation of the CaSR gene is also detected in the absence of chromosomal losses and/or P2 hypermethylation, additional mechanisms of transcriptional regulation are being examined.
The CaSR is believed to reduce parathyroid cell proliferation since downregulation or inactivating mutations of this gene in humans (39) and knockout mice (40) are associated with parathyroid hyperplasia. In neuroblastoma cell lines, in vitro proliferation rates of CaSRoverexpressing clones were significantly reduced compared with controls, and their capacity to generate tumors in immunocompromised mice was almost abolished.
Thus, to gain further insight into the mechanisms promoted by the CaSR in neuroblastoma cells, we took advantage of an in vitro model that has been widely used to characterize signaling pathways activated by this GPCR in different cellular contexts (41) (42) (43) . Interestingly, upon acute exposure to calcium, CaSR-overexpressing neuroblastoma cells underwent apoptosis. It has been reported that re-expression of genes whose DNA methylation is necessary for cancer cell survival leads to increased cell death (44) . Our data show that re-expression and activation of the CaSR induces apoptosis in two neuroblastoma cell lines in which this gene is downregulated by promoter hypermethylation. This would support the hypothesis that epigenetic silencing of the CaSR gene is neither an in vitro artefact in neuroblastoma cell lines nor a collateral 'passenger' event in primary neuroblastic tumors, but a mechanism relevant for neuroblastoma survival.
Among signaling cascades potentially involved in this apoptotic process, we chose to examine ERK1/2, the two isoforms of ERK. PARP cleavage and caspase-3 activation were analyzed by immunoblot using β-tubulin as internal loading control.
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A large body of evidence indicates that ERK1/2 may mediate proliferation, migration, differentiation and several mechanisms of cell death (45) . In numerous contexts, cell death mediated by the RasRaf-MEK-ERK pathway is dependent on sustained phosphorylation of ERK1/2 (46) . This was also the case in our in vitro model. In the presence of a MEK inhibitor, activation of ERK1/2 was remarkably reduced and similar levels of apoptosis were detected in control and CaSR-overexpressing cells exposed to calcium. This would indicate that apoptosis induced by activation of the CaSR in neuroblastoma cells is, at least, partially dependent on ERK1/2 activation.
In this in vitro model, the CaSR is expressed at much higher levels than those detected in primary neuroblastic tumors. Moreover, activation of this receptor in primary tumors is more likely to happen not acutely but in a sustained way. Therefore, specific models to analyze these potential differences are currently being developed. However, ectopic overexpression induced by stable transfection is the model most commonly used to show the deleterious effects of a potential tumor suppressor gene on cancer cell survival, proliferation and tumorigenic capacities. And, in the present context, it has contributed to provide evidence that epigenetic silencing of the CaSR gene is a relevant mechanism for neuroblastoma survival and growth.
Altogether, our data would be consistent with a tumor-suppressor role of the CaSR in neuroblastic tumors. Potential therapeutic opportunities derived from these findings are currently being explored.
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